2024 ACMG Annual Clinical Genetics Meeting
Tracking # 20-1123664
Price not reported
There are no ratings for this course
Learn moreCourse overview
The 2024 ACMG Annual Clinical Genetics Meeting will present both research and clinical topics that promote the science and the practice of clinical genetics and genomics. Sessions will focus on the latest discoveries of the etiology and the pathogenesis of genetic disorders, the latest developments in genetic testing and screening, the laboratory's role in the diagnosis of genetic disorders, the treatment of genetic disorders in children and adults, the delivery of genetic services, and more.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Clinical Laboratory Personnel
Clinical Laboratory Director
Clinical Laboratory Supervisor
Clinical Laboratory Technician
Clinical Laboratory Technologist
Public Health Director
Public Health Supervisor
Public Health Technologist
Disclosure statements
The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.
ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships listed have been mitigated.